Endo Health Solutions’ Qualitest subsidiary has reached an agreement to acquire Boca Pharmacal, a specialty generics company, for $225 million in cash.  The acquisition will expand Endo’s Qualitest business platform and pipeline of specialty products.   Boca Pharmacal focuses on niche areas, developing products such as controlled substances, semisolids and solutions. The transaction, subject to standard regulatory requirements, is expected to close before the end of the year.     “Th...